TBG Diagnostics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 10/30/2015)
| Balance Sheet | Total Assets | 25,000,000.00 | ROE | – |
| Balance Sheet | Total Equity | 23,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1,260,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -5,650,000.00 | – | – |
| Cashflow | Operating Cash Flow | -4,390,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.01 | Div. Yield | – |
| Income | Net Income | -12,000,000.00 | P/E | – |
| Income | Shares Outstanding | 185,000,000.00 | P/B | – |
| Income | Total Revenue | 3,270,000.00 | P/S | – |
Ratios calculated on: –
Company Description
TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.tbgbio.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more